PDT Partners LLC Reduces Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

PDT Partners LLC lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 36.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,618 shares of the company's stock after selling 3,165 shares during the quarter. PDT Partners LLC's holdings in Medpace were worth $1,866,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in MEDP. AQR Capital Management LLC raised its position in Medpace by 31.3% in the 4th quarter. AQR Capital Management LLC now owns 480,186 shares of the company's stock worth $159,532,000 after purchasing an additional 114,436 shares during the period. Northern Trust Corp raised its holdings in shares of Medpace by 13.2% in the fourth quarter. Northern Trust Corp now owns 248,142 shares of the company's stock worth $82,440,000 after buying an additional 28,968 shares during the period. Beacon Pointe Advisors LLC lifted its stake in shares of Medpace by 11.5% during the 4th quarter. Beacon Pointe Advisors LLC now owns 7,608 shares of the company's stock worth $2,528,000 after acquiring an additional 787 shares during the last quarter. Vulcan Value Partners LLC boosted its holdings in Medpace by 119.8% during the 4th quarter. Vulcan Value Partners LLC now owns 101,338 shares of the company's stock valued at $33,668,000 after acquiring an additional 55,237 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in Medpace in the 4th quarter valued at $5,987,000. Institutional investors own 77.98% of the company's stock.

Medpace Trading Up 0.2 %

Shares of MEDP traded up $0.53 during trading hours on Monday, hitting $305.64. The company had a trading volume of 72,877 shares, compared to its average volume of 342,319. The company has a market capitalization of $8.78 billion, a PE ratio of 24.20, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $459.77. The company's fifty day moving average price is $309.90 and its two-hundred day moving average price is $330.04.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The business had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same period in the previous year, the company posted $3.20 earnings per share. Analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares in the company, valued at approximately $904,856.36. This represents a 36.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 20.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of recent analyst reports. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and lowered their price objective for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price on the stock. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Finally, Robert W. Baird dropped their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.